Clinical trials: Stage IB Esophageal Adenocarcinoma
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy
This is an open-label, single-arm, single-center Phase Ib/II study to exploratorily evaluate the tolerability, safety, and efficacy of regorafenib and nivolumab plus chemotherapy in patients with unresectable advanced/recurrent…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT05394740
- Testing
- Regorafenib, Nivolumab, CapeOX
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- National Cancer Center Hospital East
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma
The ongoing study is a Phase II, open-label study to evaluate the efficacy of MBP-426 at a dose of 170 mg/m2 in combination therapy in patients with second line metastatic gastric, gastro-esophageal junction or esophageal…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT00964080
- Testing
- MBP-426/Leucovorin/5-FU
- Where
- 5 sites in United States, Georgia
- Volunteers
- 62 people
- Sponsor
- Mebiopharm Co., Ltd
Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Adenocarcinoma AJCC v7
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
This phase IB/II trial studies the side effects of taladegib, paclitaxel, carboplatin, and external beam radiation therapy and to see how well they work in treating patients with esophageal or gastroesophageal junction cancer…
- Conditions
- Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Adenocarcinoma AJCC v7, Stage II Esophageal Adenocarcinoma AJCC v7, Stage IIA Esophageal Adenocarcinoma AJCC v7
- Trial name
- NCT02530437
- Testing
- Carboplatin, External Beam Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
RATIONALE: PET scans done during chemotherapy may help doctors assess a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT01333033
- Testing
- Oxaliplatin, Leucovorin Calcium, Fluorouracil
- Where
- 68 sites in United States
- Volunteers
- 257 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Locally Advanced or Metastatic Solid Tumors, NSCLC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
- Trial name
- NCT05581004
- Testing
- Enzelkitug, Atezolizumab, Pembrolizumab
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 165 people
- Sponsor
- Genentech, Inc.
Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma
The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
The purpose of this study is to preliminarily evaluate anti-tumor activity of a Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Infusion (JS001) in treating advanced gastric adenocarcinoma, esophageal squamous cell…
- Conditions
- Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT02915432
- Testing
- 3 mg/kg anti-PD-1 mAb JS001 Q2W, 360 mg anti-PD-1 mAb JS001 Q3W, 240mg anti-PD-1 mAb JS001 Q3W
- Where
- 23 sites in China
- Volunteers
- 401 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
RATIONALE: Everolimus may stop the growth of stomach or esophageal cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and oxaliplatin, work in different ways to stop…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT01231399
- Testing
- fluorouracil, leucovorin calcium, oxaliplatin
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Esophageal Cancer
Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and capecitabine, work in different ways to kill tumor cells or stop them from growing. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00509561
- Testing
- cetuximab, capecitabine, cisplatin
- Where
- 55 sites in United Kingdom
- Volunteers
- 259 people
- Sponsor
- Wales Cancer Trials Unit
Stage IB Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma
Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy
This randomized pilot phase II trial studies how well molecular phenotyping works in predicting response in patients with stage IB-III esophageal cancer who are receiving carboplatin and paclitaxel or oxaliplatin, leucovorin…
- Conditions
- Stage IB Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma
- Trial name
- NCT02392377
- Testing
- Paclitaxel, Carboplatin, Oxaliplatin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Case Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, esophageal squamous cell carcinoma…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT05462873
- Testing
- QEQ278
- Where
- 12 sites in United States, Belgium and 7 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
The goal of this clinical trial is to learn whether the Ad5.F35-hGCC-PADRE vaccine is safe and can stimulate an immune response against gastrointestinal (GI) cancers in patients with pancreatic, colorectal, esophageal, gastric…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Clinical Stage II Gastric Cancer AJCC v8
- Trial name
- NCT04111172
- Testing
- Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Thomas Jefferson University
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
This randomized phase III trial studies how well radiation therapy, paclitaxel, and carboplatin with or without trastuzumab work in treating patients with esophageal cancer.
- Conditions
- Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7
- Trial name
- NCT01196390
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 634 sites in United States
- Volunteers
- 203 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
With this trial, we aim to evaluate a new combination therapy with tislelizumab and FLOT chemotherapy before surgery (neoadjuvant) for locally advanced, resectable adenocarcinoma of the esophagus or stomach (EGA).
- Conditions
- Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Resectable Esophagogastric Adenocarcinoma
- Trial name
- NeoTISLEGA (NCT07059299)
- Testing
- Tislelizumab, FLOT Chemotherapy
- Where
- 4 sites in Germany
- Volunteers
- 18 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
GC/GEJC
Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma
This is an open-label, dose-escalation and dose-expansion phase Ib/IIa clinical study to evaluate the safety, tolerability, and preliminary efficacy of HCB101 in combination therapies in subjects with gastric or GEJ…
- Trial name
- HCB101 GC GEJ (NCT07680569)
- Testing
- Zolbetuximab, Oxaliplatin + 5-Fluorouracil/Leucovorin, CAPOX (oxaliplatin/capecitabine)
- Volunteers
- 40 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
This study examines at-home monitoring of patient-generated phsyiologic health data and patient-reported outcomes. Patient-generated health data using at-home monitoring devices and smart device applications are used more and…
- Conditions
- Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage I Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04501913
- Testing
- Patient Monitoring, Questionnaire Administration
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- City of Hope Medical Center
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8
Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes
This trial studies cardiac changes after radiation or chemo-radiation for the treatment of lung or esophageal cancer that has not spread to other places in the body (non-metastatic) or has not come back (non-recurrent).
- Conditions
- Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8
- Trial name
- NCT04183218
- Testing
- Biospecimen Collection, Cardiac Event Monitor, Chemoradiotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Cancer
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
RATIONALE: Learning about the relationship between platinum levels in the blood and neurotoxicity in patients receiving oxaliplatin may help plan treatment and may help patients live more comfortably.
- Trial name
- NCT00274885
- Testing
- oxaliplatin, management of therapy complications
- Where
- 6 sites in France
- Volunteers
- 58 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
The purpose of this study is to test the safety of adding a new drug, durvalumab (also called MEDI4736), to chemoradiation with either FOLFOX/Capeox or carboplatin and paclitaxel, following initial chemotherapy with FOLFOX.
- Trial name
- NCT02962063
- Testing
- durvalumab, carboplatin AUC 2/paclitaxel, External beam radiation (EBRT)
- Where
- 7 sites in United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center